Certain Cyp3a Substrates has 2 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Mitotane, Pimavanserin. Patients taking Certain Cyp3a Substrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 2
- Major
- 2
Major (2)
- Certain Cyp3a Substrates + Mitotane— Mitotane is a strong CYP3A inducer that may decrease levels of CYP3A substrates, potentially leading to serious therapeu…
- Certain Cyp3a Substrates + Pimavanserin— Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia. Avoid combination.